Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short ...
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing ...
Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...
Aigen Investment Management LP reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 81 ...
In exchange, Arrowhead will receive an upfront payment of $500 million and an equity investment of $325 million in its common stock. The company will also receive $250 million in annual installments ...
In trading on Tuesday, shares of Sarepta Therapeutics Inc (Symbol: SRPT) crossed above their 200 day moving average of $129.96, changing hands as high as $131.00 per share. Sarepta Therapeutics ...
Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the December 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our P/B Growth Investor model based on the published ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback